GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, has entered a research collaboration with EVerZom to explore exosome-based regenerative approaches for Acute-on-Chronic Liver Failure (ACLF).
Under the agreement, the companies will conduct exploratory studies evaluating the efficacy of EViv, EVerZom’s investigational exosome therapy, in ACLF. The collaboration includes a decision point within 18 months to determine whether the candidate should advance into clinical development.
“Through this collaboration, GENFIT has exclusive rights to explore a novel mechanism of action supporting organ repair, complementing our existing programs G1090N, SRT-015, and CLM-022,” said Pascal Prigent, CEO of GENFIT. “Our shared goal is to generate rapid proof-of-concept data to assess EViv’s potential for clinical use.”
EViv utilizes a proprietary exosome platform that leverages the regenerative and immunomodulatory properties of mesenchymal stem-cell-derived exosomes. If preclinical results are positive, GENFIT will have the option to obtain exclusive licensing rights in the liver disease field to move EViv into clinical stages.
The collaboration merges EVerZom’s expertise in exosome engineering and production with GENFIT’s leadership in ACLF research, aiming to accelerate the development of regenerative treatments.
“Our goal is to push the boundaries of gene and cell therapies and open new avenues for regenerative medicine,” said Jeanne Volatron, CEO and co-founder of EVerZom. “ACLF is a key indication for positioning EViv, and GENFIT’s proven track record in this field makes it an ideal partner to advance preclinical work toward the clinic.”
Exosomes — nanosized vesicles secreted by cells — play a vital role in intercellular communication by transporting proteins, RNAs, and other biomolecules. Compared with stem cells themselves, exosomes offer advantages such as greater stability, reduced biological variability, enhanced safety, and simplified hospital logistics through easier storage and availability.
GENFIT is a biopharmaceutical company specializing in therapies for rare and severe liver diseases with significant unmet medical needs. With over two decades of expertise, the company continues to advance novel therapeutic approaches targeting complex liver pathologies.
EVerZom is a French biotechnology firm developing next-generation regenerative therapies based on mesenchymal stem-cell-derived exosomes. Its proprietary bioproduction platform supports high-yield, GMP-compliant manufacturing and innovative formulations that enhance the therapeutic potential of exosomes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!